Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400816 | 0.83 | MAPT (0.79) | LGMNALDH1A1MAPTPDK2POLB | |
| SCHEMBL38658281 | 0.81 | LGMN (0.76) | LGMNALDH1A1MAPTPDK2SHMT2 | |
| SCHEMBL27543 | 0.78 | LGMN (0.70) | LGMNALDH1A1MAPTPDK2SHMT2 | |
| SCHEMBL655166 | 0.77 | LGMN (0.70) | LGMNALDH1A1MAPTPDK2SHMT2 | |
| SCHEMBL21533588 | 0.77 | LGMN (0.69) | LGMNALDH1A1MAPTPDK2KDM4E | |
| SCHEMBL15850037 | 0.75 | MAPT (0.71) | LGMNALDH1A1MAPTPDK2KDM4E | |
| SCHEMBL6499815 | 0.75 | TSHR (0.66) | LGMNALDH1A1MAPTPDK2KDM4E | |
| SCHEMBL21533589 | 0.75 | LGMN (0.66) | LGMNALDH1A1MAPTPDK2KDM4E | |
| SCHEMBL20495080 | 0.74 | LGMN (0.65) | LGMNALDH1A1MAPTPDK2SHMT2 | |
| SCHEMBL6510233 | 0.74 | LGMN (0.59) | LGMNALDH1A1MAPTPDK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101774-B2 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-1803452-A1 | ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | MTTP, CETP, LIPA | LGMN 1963/4885ALDH1A1 421/4885MAPT 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.